Skip to content
Study details
Enrolling now

Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV

University of Hawaii
NCT IDNCT06935838ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

12

Study length

about 9 months

Ages

18+

Locations

1 site in HI

What this study is about

This trial is testing whether tirzepatide helps with weight loss and reduces chronic inflammation in people living with HIV. Participants will receive tirzepatide, a medication, for 261 days. It aims to measure changes in weight, body composition, liver health, inflammatory markers, and other factors.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Tirzepatide

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IV

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

tirzepatide

Drug routes

injection (Injection)

Endpoints

Primary: Change in Baseline Body Weight

Secondary: Body composition, Change in Inflammatory Markers: IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, Waist circumference

Body systems

Immune, Infectious